Long-Term Follow-Up of At Least Five Years After Recombinant Human Thyrotropin Compared to Levothyroxine Withdrawal for Thyroid Remnant Ablation with Radioactive Iodine
Restricted accessLetterFirst published online March, 2012
Long-Term Follow-Up of At Least Five Years After Recombinant Human Thyrotropin Compared to Levothyroxine Withdrawal for Thyroid Remnant Ablation with Radioactive Iodine
RosarioPW, BorgesMA, PurischS. 2008. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med, 49:1776–1782.
2.
RosarioPW, SallesDS, PurischS. 2009. Area under the curve of TSH after levothyroxine withdrawal versus administration of recombinant human TSH (rhTSH): possible implications for tumor growth. Arq Bras Endocrinol Metabol, 53:767–770.
3.
RosarioPW, Malard XavierAC, CalsolariMR. 2010. Recombinant human TSH (rhTSH) in thyroid remnant ablation with 131-iodine in high risk patients. Thyroid, 20:1247–1252.
4.
RosarioPW, Malard XavierAC. 2011. Recombinant human TSH (rhTSH) in thyroid remnant ablation with 1.1 GBq 131-iodine in low risk patients. Am J Clin Oncol [Epub ahead of print]10.1097/COC.0b013e318201a41a.
